Merck's Premium Price: Is It Worth the Bet?
The pharmaceutical industry is witnessing a stark valuation mismatch between Merck (MRK) and Eli Lilly (LLY), two direct rivals competing for healthcare dollars. While Merck's operating profit has fallen by nearly 65% in the last year, its price-to-operating income ratio has risen to 52.2 times, outpacing Eli Lilly's 25.3 times.
This reversal from a year ago has left investors questioning what has changed to justify Merck's premium and what exactly that premium buys today. The company's pipeline is expected to transform its portfolio with over 20 new products, with recent progress suggesting this is more than just a forecast. The FDA recently approved Lipfendra, the first oral PCSK9 inhibitor for high cholesterol.
Merck's premium is partly mathematical and partly based on optimism about its pipeline. Management has highlighted more than $70 billion of commercial opportunity from these new products, which are expected to offset the eventual patent expiration of Keytruda. However, the market's willingness to look past Merck's trailing operating income collapse rests entirely on this pipeline optimism.
The decision between Merck and Eli Lilly hinges on which growth narrative an investor finds more compelling. Merck's premium is a bet that its deep and diversifying pipeline will successfully navigate the company into the next decade, while Eli Lilly offers a story of rapid scale with explosive growth from its current blockbuster portfolio.